cystamine has been researched along with Alzheimer Disease in 2 studies
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eslami, M | 1 |
| Hashemianzadeh, SM | 1 |
| Bagherzadeh, K | 1 |
| Seyed Sajadi, SA | 1 |
| Minarini, A | 1 |
| Milelli, A | 1 |
| Tumiatti, V | 1 |
| Rosini, M | 1 |
| Simoni, E | 1 |
| Bolognesi, ML | 1 |
| Andrisano, V | 1 |
| Bartolini, M | 1 |
| Motori, E | 1 |
| Angeloni, C | 1 |
| Hrelia, S | 1 |
2 other studies available for cystamine and Alzheimer Disease
| Article | Year |
|---|---|
Molecular perception of interactions between bis(7)tacrine and cystamine-tacrine dimer with cholinesterases as the promising proposed agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Binding Sites; Catalytic Domain; Cholinesterase Inhibitors; Cholinesterases; Cyst | 2016 |
Cystamine-tacrine dimer: a new multi-target-directed ligand as potential therapeutic agent for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Cell Line, Tumor; Cell Survival; Cholinesterase Inhibitors; Cystamine; Drug Combi | 2012 |